Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 4/2017

COMPARATIVE STUDY BETWEEN THE SALES OF ANTIULCER DRUGS H2 ANTAGONISTS AND PROTON PUMP INHIBITORS

ANAMARIA BOBOIA 1*, LAVINIA ALEXANDRA FEHER 1, STANCA CUC 2, MARIOARA MOLDOVAN 2

1.“Iuliu Haţieganu” University of Medicine and Pharmacy, Faculty of Pharmacy, Pharmaceutical Management, Marketing and Legislation Department, 8 Victor Babeş St., 400012, Cluj-Napoca, Romania
2.“Babeş-Bolyai” University, “Raluca Ripan“ Institute for Research in Chemistry, 30 Fântânele St., 400294, Cluj-Napoca, Romania

Download Full Article PDF

Gastric ulcer is a frequently encountered disease, currently existing a great number of antiulcer drugs on the pharmaceutical market. The purposes of the study were to analyse the sales of the products containing active pharmaceutical ingredients (APIs) from the pharmacological classes of proton pump inhibitors (PPIs) and H2 antagonists, their comparison, highlighting the best-selling drugs of the two pharmacological classes, by underling the factors that influence them. There were analysed the quantitative sales of the products containing the common international names (INNs) from the two classes of antiulcer drugs studied, during a period of time of two years. The necessary data for the study were collected from community pharmacies, using pharmacies’ management software, the methods used in the research being: retrospective analysis, sampling method, comparison method and descriptive methods. The results showed that from the total quantities of medicines issued in the pharmacies analysed (48164 units), the PPIs represent 84.91% (40895 units), while H2 antagonists represent only 15.09% (7269 units). The best-selling common international name (INN) of the PPIs class was omeprazolum (20634 units, 50.46%) and the best-selling INN of H2 antagonists class was ranitidinum (5897 units, 81.13%). The ranking of the pharmacies analysed, in terms of sales of antiulcer drugs was conducted taking into account: regime of drug release, existence of generic drugs, pharmacies’ location and schedule, and presence or absence of medical institutions near the pharmacies.